HALO
HALOZYME THERAPEUTICS INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
HALOZYME THERAPEUTICS INC (HALO) is held as common stock by 5 tracked hedge-fund managers, with a combined reported value of ~$155.83M; the largest are Joel Greenblatt, Renaissance Technologies, Ray Dalio. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 1 added, 4 trimmed. 10 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Cooling
Common-stock holders51 also report options
Congress trades10
Price$112.89vs quarter-end+44.23%
Sectors0
This quarter's moves
Top holderNew0
Added1
Trimmed / sold4
Joel GreenblattCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $7.73M— of portfolio98,7002026 Q2
Value $2.72M— of portfolio34,7002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $7.73M | — | — |
| Ken GriffinPUT | $2.72M | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.